Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Zalifrelimab |
Synonyms | |
Therapy Description |
Zalifrelimab (AGEN1884) is an antibody that targets CTLA-4, potentially resulting in increased anti-tumor immune response (PMID: 31395100). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Zalifrelimab | AGEN-188AGEN1884|AGEN1884|UGN301|UGN 301|UGN-301 | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 149 | Zalifrelimab (AGEN1884) is an antibody that targets CTLA-4, potentially resulting in increased anti-tumor immune response (PMID: 31395100). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05375903 | Phase I | Imiquimod + Zalifrelimab Zalifrelimab | A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) | Recruiting | USA | ITA | ESP | 0 |
NCT02694822 | Phase I | Zalifrelimab | AGEN-1884, an Anti-CTLA-4 Antibody, in Advanced Solid Cancers | Completed | USA | 0 |